Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Lok

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Gastroenterology & Hepatology|September 10, 2011
Management of viral resistance in the therapy of chronic hepatitis BAnna Lok
Seminars in Liver Disease|July 20, 2006
Viral hepatitis and liver transplantationPratima Sharma, Anna Lok
Gut|April 17, 2012
Management of HBV- and HCV-induced end stage liver diseaseDavid J Mutimer, Anna Lok
Journal of the National Cancer Institute|August 13, 2008
Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinomaJosep M Llovet, Anna Lok
Gut|July 29, 2025
Partial cure of chronic hepatitis B: potential implications for HCC surveillance?Wai-Kay Seto, Anna Lok
Journal of the American Statistical Association|December 18, 2018
Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling DesignsDandan Liu, Tianxi Cai, Anna Lok, et al.
Lancet (London, England)|June 24, 2014
Hepatitis B virus infectionChristian Trépo, Henry L Y Chan, Anna Lok
The Annals of Applied Statistics|September 26, 2017
IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNSYingye Zheng, Marshall Brown, Anna Lok, et al.
Journal of Hepatology|April 29, 2015
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugsStephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, et al.
Journal of Hepatology|May 21, 2010
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic reviewGeorge V Papatheodoridis, Pietro Lampertico, Spilios Manolakopoulos, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Gastroenterology & Hepatology|September 10, 2011
Management of viral resistance in the therapy of chronic hepatitis BAnna Lok
Seminars in Liver Disease|July 20, 2006
Viral hepatitis and liver transplantationPratima Sharma, Anna Lok
Gut|April 17, 2012
Management of HBV- and HCV-induced end stage liver diseaseDavid J Mutimer, Anna Lok
Journal of the National Cancer Institute|August 13, 2008
Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinomaJosep M Llovet, Anna Lok
Gut|July 29, 2025
Partial cure of chronic hepatitis B: potential implications for HCC surveillance?Wai-Kay Seto, Anna Lok
Journal of the American Statistical Association|December 18, 2018
Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling DesignsDandan Liu, Tianxi Cai, Anna Lok, et al.
Lancet (London, England)|June 24, 2014
Hepatitis B virus infectionChristian Trépo, Henry L Y Chan, Anna Lok
The Annals of Applied Statistics|September 26, 2017
IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNSYingye Zheng, Marshall Brown, Anna Lok, et al.
Journal of Hepatology|April 29, 2015
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugsStephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, et al.
Journal of Hepatology|May 21, 2010
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic reviewGeorge V Papatheodoridis, Pietro Lampertico, Spilios Manolakopoulos, et al.
Pageof 3